FluGen tests its influenza vaccine against the wrong strain of flu — on purpose
167189
post-template-default,single,single-post,postid-167189,single-format-standard,bridge-core-1.0.5,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.1,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-6.0.2,vc_responsive
 

FluGen tests its influenza vaccine against the wrong strain of flu — on purpose

FluGen tests its influenza vaccine against the wrong strain of flu — on purpose

A Madison company that’s working on a universal influenza vaccine has started a clinical trial using its vaccine to protect against a flu strain that doesn’t match up.

FluGen says the first subject has received a dose of its M2SR vaccine, also known as RedeeFlu, in a study being conducted in Belgium.

The vaccine uses a flu strain that was in vaccines marketed during the 2008-2010 influenza seasons. People in the study will then be exposed to a flu virus tied to outbreaks of the disease in 2015.

“It’s a study that, to our knowledge, has never been done before. We’re excited to see how the vaccine performs,” FluGen CEO Paul Radspinner said.